FindTrial
Sign In

Efficacy of high-dose cytarabine combined with temozolomide in the treatment of refractory/relapsed primary central nervous system lymphoma: an analysis based on medical records

Efficacy analysis of high-dose cytarabine combined with temozolomide in the treatment of refractory/relapsed primary central nervous system lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100054482
Enrollment
Unknown
Registered
2021-12-18
Start date
2021-12-15
Completion date
Unknown
Last updated
2022-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary central nervous system lymphoma

Interventions

Case series:None

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years; gender is not limited; 2. Diagnosed with primary central nervous system lymphoma, and received high-dose cytarabine combined with temozolomide chemotherapy; 3. Those who understand and sign the informed consent; 4. Informed consent for the entry of biobanks has been signed.

Exclusion criteria

Exclusion criteria: 1. The blood samples in the biobank are insufficient to detect genomic DNA; 2. The lack of clinical data cannot evaluate the efficacy.

Design outcomes

Primary

MeasureTime frame
Progression-free survival;—

Secondary

MeasureTime frame
Overall survival;—

Countries

China

Contacts

Public ContactChen Bobin
bbchen@fudan.edu.cn+86 13402186236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026